BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 12845624)

  • 1. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of HER2 protein in breast cancer is biologically significant.
    Tovey SM; Reeves JR; Stanton P; Ozanne BW; Bartlett JM; Cooke TG
    J Pathol; 2006 Nov; 210(3):358-62. PubMed ID: 16981252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
    Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
    Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer.
    Witton CJ; Hawe SJ; Cooke TG; Bartlett JM
    Histopathology; 2004 Jul; 45(1):47-54. PubMed ID: 15228443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G;
    Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
    Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor changes during breast cancer metastasis.
    Fuchs IB; Siemer I; Bühler H; Schmider A; Henrich W; Lichtenegger W; Schaller G; Kuemmel S
    Anticancer Res; 2006; 26(6B):4397-401. PubMed ID: 17201160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
    Memon AA; Sorensen SB; Nexo E
    Scand J Clin Lab Invest; 2006; 66(7):623-30. PubMed ID: 17101554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
    J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.